Structured reporting to improve transparency of analyses in prognostic marker studies

Table 8 Overview of several criteria and assessment of the quality of reporting

ID	Study	Journal	Markers	Outcomes	Variables	Events for primary outcome	Events for all outcomes reported	Information on exclusions^a	Subgroup analysis^b
b1	Hayashi	BCRT	1	1	3	Unknown	No	3^c
b2	Huzell	BCRT	1	2	7	100	Yes	3	2
b3	Jerzak	BCRT	2	2	14	36	Yes	2
c1	Billingsley	Cancer	1	2	8	Unknown	No	3
c2	Huang	Cancer	3	2	8	257	Yes	3	2
c3	Price	Cancer	1	1	9	Unknown	No	1	0
e1	Gonzalez-Vallinas	EJC	1	1	9	22	Yes	2
e2	Hokuto	EJC	1	5	13	86	No	1
e3	Thurner	EJC	1	3	6	24	Yes	2	0
i1	Keck	IJC	2	2	10	Unknown	No	1	0
i2	Roedel	IJC	2	4	7	27	Yes	1	1
i3	Schirripa	IJC	3	1	11	Unknown	No	1	0
j1	Martin	JCO	2	1	8	6294	Yes	3	2
j2	Ostronoff	JCO	2	6	10	Unknown	No	2	2
j3	Xing	JCO	1	1	9	338	Yes	1	2

BCRT Breast Cancer Research and Treatment, EJC European Journal of Cancer, IJC International Journal of Cancer, JCO Journal of Clinical Oncology
^aCompleteness of information on exclusions: 3, exclusion criteria and number of exclusions known; 2, exclusion criteria listed, but number of excluded patients unknown; and 1, exclusion criteria not listed
^bSubgroup analysis: 2, subgroup analyses performed and sample size and number of events given for at least one subgroup analysis; 1, subgroup analyses performed and sample size given for at least one subgroup analysis, but number of events not known; and 0, subgroup analyses performed, but no sample size or number of events given
^cNote: reference to a previous study by the authors is required

ISSN: 1741-7015